391
Views
6
CrossRef citations to date
0
Altmetric
Cornea

Wound Healing and Mucin Gene Expression of Human Corneal Epithelial Cells Treated with Deproteinized Extract of Calf Blood

ORCID Icon & ORCID Icon
Pages 1181-1188 | Received 03 Sep 2018, Accepted 10 Jun 2019, Published online: 05 Jul 2019
 

ABSTRACT

Purpose: The function of Solcoseryl in the corneal epithelium has not been fully examined. Here, we investigated the roles of Solcoseryl in the regulation of gene expression and corneal epithelial cell (CEC) activity.

Materials and Methods: The effect of Solcoseryl on CEC activity was analyzed through cell migration, adhesion, proliferation, and wound healing assays. Analysis of gene expression was conducted via western blotting and quantitative reverse transcription polymerase chain reaction (PCR).

Results: The results demonstrated that Solcoseryl increased the adhesion, migration, proliferation, and wound healing of CECs. Analysis of gene expression showed that Solcoseryl-stimulated CECs exhibited increased expression of mucin family genes, such as MUC1, −5AC, −7, and −16. Solcoseryl also increased the activities of the intracellular signaling molecules AKT, FAK, ERK, and Src in CECs. Using pharmacologic inhibitors of ERK and AKT, we showed that the expression of mucin genes by Solcoseryl is mediated by the activation of ERK and AKT signaling.

Conclusions: Our findings demonstrate that Solcoseryl may contribute to the wound healing of CECs by enhancing their migration, adhesion, and proliferation. Additionally, our results suggest that Solcoseryl has a protective effect on ocular surfaces due to its induction of the expression of mucin genes in CECs. These findings suggest that Solcoseryl is a useful therapeutic target for patients with corneal wounds.

Conflicts of interests

The authors report no conflicts of interest.

Additional information

Funding

This research was supported by a Basic Science Research Program grant through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1D1A1B03933337). Hanlim Pharmaceuticals Inc. (Seoul, Republic of Korea) provided funding for the development of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.